Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJKBWO)

Drug Name

HER2-specific CAR T cell Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Atypical teratoid/rhabdoid tumour	2A00.1Y	Phase 1	[1]
Choroid plexus carcinoma	2A02.12	Phase 1	[1]
Ependymoma	2A00.0Y	Phase 1	[1]
Gastric adenocarcinoma	2B72	Phase 1	[1]
Germ cell tumour	2C80.2	Phase 1	[1]
Glioma	2A00.0	Phase 1	[1]
Medulloblastoma	2A00.10	Phase 1	[1]
Pineoblastoma	2A00.20	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	CAR-T-Cell-Therapy	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Erbb2 tyrosine kinase receptor (HER2)	DTT	ERBB2	6.226	7.169	7.196	6.397

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Brainstem tissue

The Studied Disease

Glioma [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Erbb2 tyrosine kinase receptor (HER2)	DTT	ERBB2	1.98E-01	0.21	1.79
Erbb2 tyrosine kinase receptor (HER2)	DTT	ERBB2	2.06E-01	-0.15	-0.94

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors